TNBC patient risk groups stratified by EGFR, CK5/6, Ki-67, pT and pN.

<p>TNBC patient risk groups stratified by EGFR, CK5/6, Ki-67, pT and pN.</p

Immunoreactivity of 69-yr-old patient with T1bN0M0 TNBC.

<p>(A) Hematoxylin and Eosin (H&E), (B) EGFR (>70%), (C) CK5/6 (>70%), (D) ER, (E) PR, (F) HER2, (G) Ki-67 (>60%), and (H) P53 (>90%). The patient was undergone BCT, had 3.8 event free survival and 22.8 months overall survival.</p

Kaplan Meier curves of disease free survival of risk groups for TNBC patients.

<p>The patients were stratified into different risk groups. Two low basal (EGFR≤15% and CK5/6≤50%) risk groups: group 1 (n = 20) with low expressions/values of EGFR (≤15%), CK5/6 (≤50%), Ki-67 (≤50%), pT (≤ 3), and pN (≤ 1), and group 2 (n = 30) with low expressions of EGFR and CK5/6, and any high expressions/values of Ki-67, pT, and pN. Two high basal risk groups: group 3 (n = 106) with single high basal expression (EGFR>15% or CK5/6>50%), and group 4 (n = 36) with double high basal expressions (EGFR>15% and CK5/6>50%).</p

Patients characteristics.

<p>Patients characteristics.</p

Prognostic value of clinicopathological variables in predicting disease free survival using univariate and multivariate Cox model.

<p>Prognostic value of clinicopathological variables in predicting disease free survival using univariate and multivariate Cox model.</p